Celecoxib + Ibuprofen plus Omeprazole
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Bowel Diseases, Inflammatory
Conditions
Bowel Diseases, Inflammatory
Trial Timeline
Oct 1, 2003 → Apr 1, 2004
NCT ID
NCT00640809About Celecoxib + Ibuprofen plus Omeprazole
Celecoxib + Ibuprofen plus Omeprazole is a approved stage product being developed by Pfizer for Bowel Diseases, Inflammatory. The current trial status is completed. This product is registered under clinical trial identifier NCT00640809. Target conditions include Bowel Diseases, Inflammatory.
What happened to similar drugs?
15 of 20 similar drugs in Bowel Diseases, Inflammatory were approved
Approved (15) Terminated (3) Active (5)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00640809 | Approved | Completed |
Competing Products
20 competing products in Bowel Diseases, Inflammatory
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab + Infliximab + Infliximab | Celltrion | Approved | 50 |
| CT-P13 | Celltrion | Phase 3 | 36 |
| Subcutaneous infliximab CT-P13 Remsima®SC | Celltrion | Pre-clinical | 22 |
| fidaxomicin | Astellas Pharma | Approved | 43 |
| linaclotide + placebo | Astellas Pharma | Phase 2 | 35 |
| YM060 + Placebo | Astellas Pharma | Phase 3 | 40 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 43 |
| Enfortumab vedotin | Astellas Pharma | Phase 2 | 42 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 43 |
| YM060 | Astellas Pharma | Phase 3 | 40 |
| YM060 + placebo | Astellas Pharma | Phase 2 | 35 |
| YM060 | Astellas Pharma | Phase 3 | 40 |
| linaclotide + Placebo | Astellas Pharma | Phase 3 | 40 |
| Ramosetron | Astellas Pharma | Pre-clinical | 26 |
| YM060 | Astellas Pharma | Phase 2 | 35 |
| Naldemedine + Placebo | Shionogi | Phase 2 | 35 |
| E6007 + E6007 + E6007 + E6007 + E6007 + E6007 | Eisai | Phase 1 | 29 |
| ONO-2952 + Placebo comparator | Ono Pharmaceutical | Phase 2 | 27 |
| ONO-2952 + ONO-2952 Matching Placebo | Ono Pharmaceutical | Phase 2 | 35 |
| Placebo + MORF-057 | Eli Lilly | Phase 2 | 42 |